Table 1A.

Study Characteristics

Study #	Author (Year)	Patients, N	Randomized	Placebo	Quality Score (0–4)†	NAC Dosing (Total Dose, Grams)	Mean Contrast Volume (ml) NAC/Controls	Type of IVF	% DM NAC/Controls
1	Kay (2003)	200	Y	Y	1	600 mg BID (2.4)	130/120	.9 NS	40/36
2	Baker (2003)	80	Y	N	0	150 mg/kg IV	238/222	.9 NS	41/44
3	Shyu (2002)	121	Y	Y	0	400 mg BID (1.6)	119/115	.45 NS	63/64
4	Ochoa (2002)*	100	Y	Y	0	1,000 mg (2)	132/150	.45 NS	‡
5	Durham (2002)	81	Y	Y	2	1,200 mg (1.4)	77.4/84.7	.45 NS	50/46.3
6	Diaz-Sandoval (2002)	54	Y	Y	2	600 mg BID (2.4)	179/189	.45 NS	48/52
7	Briguori (2002)	183	Y	N	0	600 mg BID (2.4)	194/200	.45 NS	43/32.5
8	Allaqaband (2002)	126	Y	N	1	600 mg BID (2.4)	‡	.45 NS	53/43
9	Tepel (2000)	83	Y	Y	0	600 mg BID (2.4)	75	.45 NS	32/33
10	Boccalandro (2003)	181	N	N	2	600 mg BID (2.4)	192/191	‡	67/57
11	Vallero (2002)	101	Y	N	0	600 mg BID (2.4)	203	0.9 NS	14.6/30
12	Mouhayar (2002)*	110	N	N	1	unclear	‡	‡	‡
13	Kahlon (2002)*	51	Y	Y	0	600 mg BID (2.4)	‡	.9 NS	‡
14	Erickson (2002)*	139	N	N	0	unclear	‡	‡	‡
15	Adamian (2002)*	57	N	N	1	600 mg BID (unclear)	273/303	‡	57/70

Studies included in the analysis are listed above the solid line, while excluded studies are listed below the solid line. All studies used IV hydration pre- and postcontrast administration. All studies enrolled>90% of patients undergoing cardiac catheterization, except for Tepel et al.²⁸, which enrolled patients undergoing CT scanning. Briguori et al.⁴¹ and Bader et al.⁴⁰ are not included in the table because they both had another active treatment arm, but no control group. Kay et al.²² reported median contrast volume rather than mean contrast volume.

^*Articles found only in abstract form.

^†Define quality score as 1 point for each of the following: appropriate randomization, allocation concealment, blinded patients, and blinded providers.

^‡Value unclear from provided data.

NAC, N-acetylcysteine; NS, normal saline; BID, twice daily; IVF, intravenous fluids; DM, diabetes.